Proteasome Activator Complex Subunit 3 (PSME3) Antibody 供应商 Abbexa 产品货号 abx110126 产品报价 ￥询价/20ug ￥询价/50ug ￥询价/100ug ￥询价/200ug ￥询价/1mg 产品说明书 点击查看 购买方式 银行转账、电汇、支票、现金,在线支付宝及网银支付,或直接与我们电话联系400-6800-868。
上海玉博生物科技有限公司 主要致力于“Proteasome Activator 11S Complex (human) (purified) BML-PW9420-0025”的生产销售。多年的“Proteasome Activator 11S Complex (human) (purified) BML-PW9420-0025”生产与销售的经验,与各行业新老用户建立了稳定的合作关系,我
Proteasome activator complex subunit 1Prognostic biomarkerSarcomaLeiomyosarcomaSoft tissue sarcomaImmunohistochemistryPrevious studies on high grade sarcomas using mass spectrometry imaging showed proteasome activator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. ...
中文名称: HUMAN PROTEASOME ACTIVATOR COMPLEX SUBUNIT 1(PSME1) ELISA KIT 中文同义词: HUMAN PROTEASOME ACTIVATOR COMPLEX SUBUNIT 1(PSME1) ELISA KIT;人蛋白酶体激活剂复合物亚基1(PSME1)酶联免疫试剂盒 英文名称: Human Proteasome activator complex subunit 1(PSME1) ELISA kit 英文同义词: Human Proteasome...
人蛋白酶体激活剂复合物亚基1(PSME1)酶联免疫试剂盒;HUMAN PROTEASOME ACTIVATOR COMPLEX SUBUNIT 1(PSME1) ELISA KIT CBNumber: CB96903126 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商2 HUMAN PROTEASOME ACTIVATOR COMPLEX SUBUNIT 1(PSME1) ELISA KIT化学性质 ...
NSC697923 AG-CR1-3519 Selective Ub-conjugating enzyme (E2) complex Ubc13-Uev1A inhibitor. Inhibits the formation of the Ubc13~Ub conjugate. Oridonin CDX-O0131 CRL/SCF RING E3 activator. Activates Fbw7 an E3 ubiquitin ligase (CRL/SCF RING) of c-Myc and promotes proteasomal degradation. Simva...
摘要: 3P044 Free energy landscape of substrate passing inside proteasome-activator complex(01A. Protein: Structure,Poster) Ishida Hisashi Biophysics 53(SUPPLEMENT_1-2), S219, 2013-09-13DOI: 10.2142/biophys.53.s219_2 年份: 2017 收藏 引用 批量引用 报错 分享 全部来源 求助全文 ResearchGate j...
For decades, antigen presentation on major histocompatibility complex class I for T cell-mediated immunity has been considered the primary function of proteasome-derived peptides1,2. However, whether the products of proteasomal degradation play addi
(G) Assessment of proteasome activity in HepG2 cells treated with additional NMDA receptor antagonists (memantine, MK801-20 µM), a proteasome activator (IU1-50 µM), and an inhibitor (MG132-0.5 µM). (H–J) Proteasome inhibition by MG132 prevents the reduction of IDPs such as ...
but one possibility is that they function in the context of hybrid proteasomes, in which they bind to the opposite end of the 20S proteasome from an 19S activator, and through as-yet-uncharacterized interactions localize the degradative capacity of the 19S activator complex to a specific cellula...